VJOncology is committed to improving our service to you

ASCO 2020 | HERO phase III trial in advanced prostate cancer

VJOncology is committed to improving our service to you

Neal Shore

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, USA, discusses data coming from the HERO phase III study (NCT03085095) comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter